Application of terbinafine in preparation of synergist for PD1 monoclonal antibody treatment of viral liver cancer and viral liver cancer combined treatment drug
Through the combined use of terbinepin and PD1 monoclonal antibody, CD8 T cells are activated, which significantly improves the therapeutic effect of viral liver cancer, solves the problem of low response rate for single-agent PD1 treatment in the prior art, and achieves more Effective tumor suppression and prolonged survival time.
Patent Information
- Application Number
- CN202410911764.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-09
- Publication Date
- 2024-11-08
AI Technical Summary
Current patients with viral liver cancer (HBV-HCC) have low response rate to single-agent PD1 treatment, limited efficacy, and lack effective efficacy enhancing options.
Using terbinepin and PD1 monoclonal antibody in combination, by activating the T cell immune function of CD8, it significantly inhibits tumor volume, weakens tumor cells' invasion and involves liver, and prolongs survival time.
Terbinepin combined with PD1 monoclonal antibody significantly improves the treatment response rate of viral liver cancer, significantly inhibits tumor growth, prolongs the survival time of mice, and attenuates the invasion of tumor cells on the liver, providing a new targeted therapeutic strategy.
Smart Images

Figure CN118903080A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology. More specifically, it relates to the use of terbinafine in the preparation of a synergist for treating viral liver cancer with PD1 monoclonal antibody, and a terbinafine combined with PD1 monoclonal antibody combined drug with enhanced efficacy in treating viral liver cancer. Background Art
[0002] Hepatocellular carcinoma (HCC) is the main type of primary liver cancer. The early symptoms of HCC are not obvious, and most patients are already in the middle and late stages when they are clinically diagnosed, losing the opportunity for radical resection of HCC. Sorafenib and lenvatinib are the first-line targeted drug regimens recommended by the current NCCN guidelines for advanced HCC, but the efficacy is limited and the patient's survival can only be extended by about 3 months. There are many causes of HCC and the molecular mechanism is not yet fully understood. Most scholars believe that its onset is a complex process with multiple factors and steps, which is affected by factors such as the environment and diet. Therefore, the treatment plan is not accurate. The effective treatment strategies for different types of liver cancer are diverse and the efficacy is detailed. The most common HCCs include HBV infection-induced liver cancer (HBV-HCC) and metabolic dysfunction-related fatty liver induced hepatocellular carcinoma (MASH-HCC). Among them, patients with viral liver cancer (HBV-HCC) account for more than 80% of the total number of HCC patients.
[0003] In recent years, significant progress has been made in the systemic treatment of HCC, especially immunotherapy strategies have brought new options for the treatment of hepatocellular carcinoma. However, the effectiveness of single-drug PD-1 / PD-L1 treatment for patients with advanced hepatocellular carcinoma is only 15%-20%. Due to the low response rate and limited efficacy of single immune drug treatment, the clinical benefits are limited to a small number of patients. There is still an urgent need to develop new treatment strategies. With the advancement of medical technology, immunotherapy combined with targeted therapy has become a new trend in the treatment of hepatocellular carcinoma. For example, "A Case of Targeted Combined Immunotherapy for Advanced Liver Cancer, Yin Xuehong, 2022" disclosed a clinical case of using apatinib mesylate combined with toripalimab to treat advanced liver cancer. However, there are fewer targeted drugs that enhance the efficacy of PD1 and have good safety. Yu Jun's team published a research paper titled "Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma" online in Gut, and found that targeting squalene epoxidase can restore the anti-PD-1 efficacy of metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma (MASH-HCC), but also proposed that this regimen is only applicable to MASH-HCC; the article disclosed that in recent years, immune checkpoint inhibitors (ICIs) have become one of the most promising strategies in cancer treatment. ICIs targeting programmed cell death protein 1 (PD-1) have been approved for the treatment of advanced HCC, with an overall response rate ranging from 7% to 36%; in contrast to the responsiveness of virus-related HCC to ICI treatment, whether MASH-HCC responds to ICI treatment is still far from certain; two studies have shown that MASH-HCC responds poorly to ICIs in both human patients and mouse models. Both indicate that the treatment mechanisms and treatment plans of HBV-HCC and MASH-HCC are significantly different.
[0004] Therefore, exploring the synergistic effect of PD1 monoclonal antibody treatment for viral liver cancer is of great significance for the treatment of viral liver cancer, which has a huge patient population. Summary of the invention
[0005] The present invention aims at the shortcomings of existing viral liver cancer (HBV-HCC) treatment strategies and the clinical problem of low response rate of patients with single-drug PD1 treatment of viral liver cancer (HBV-HCC), and provides a target-immune combination strategy for treating viral liver cancer (HBV-HCC). Specifically, it relates to the use of terbinafine in the preparation of a synergist for PD1 monoclonal antibody treatment of viral liver cancer, and a terbinafine combined with PD1 monoclonal antibody combined drug with enhanced efficacy in treating viral liver cancer.
[0006] The first objective of the present invention is to provide the use of terbinafine in preparing a synergist for the treatment of viral liver cancer with PD1 monoclonal antibody.
[0007] The second object of the present invention is to provide the use of terbinafine combined with PD1 monoclonal antibody in the preparation of a drug for treating viral liver cancer.
[0008] The third object of the present invention is to provide a combined drug of terbinafine combined with PD1 monoclonal antibody with enhanced efficacy in treating viral liver cancer.
[0009] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0010] The hepatocellular carcinoma model modeled by subcutaneous injection of mouse hepatocellular carcinoma Hepa1-6, and the spontaneous hepatocellular carcinoma model induced by high-pressure tail vein injection of tumor plasmids are commonly used models for studying viral liver cancer. The present invention uses these two animal models to study the synergistic scheme of PD1 monoclonal antibody in the treatment of viral liver cancer (HBV-HCC). The present invention compares and analyzes the effects of single medication and combined medication, and finds that terbinafine can effectively enhance the anti-viral liver cancer immunity of PD1 monoclonal antibody, and the combined strategy significantly improves the anti-viral liver cancer effect, which can significantly inhibit the increase of tumor volume, reduce the degree of invasion of tumor cells to the liver, and prolong the survival time of tumor mice. Therefore, the present invention claims protection of the following application schemes:
[0011] Application of terbinafine in the preparation of a synergist of immunotherapy drugs for viral liver cancer.
[0012] Application of terbinafine in preparing medicine for treating viral liver cancer.
[0013] Application of terbinafine combined with immunotherapy drugs in the preparation of drugs for enhancing the efficacy of viral liver cancer.
[0014] Application of terbinafine combined with immunotherapy drugs in the preparation of drugs for treating viral liver cancer.
[0015] Preferably, the above-mentioned immunotherapy drug is PD1 monoclonal antibody.
[0016] Specifically, the drug refers to a drug that can inhibit the increase in the volume of viral liver cancer tumors.
[0017] Specifically, the drug refers to a drug that can prolong the survival time of patients with viral liver cancer.
[0018] Specifically, the drug refers to a drug that can reduce the degree of invasion and involvement of tumor cells in viral liver cancer patients.
[0019] The present invention also provides a medicine for treating viral liver cancer, comprising terbinafine and an immunotherapy drug, and a pharmaceutically acceptable carrier.
[0020] Preferably, the immunotherapy drug is PD1 monoclonal antibody.
[0021] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0022] The present invention provides a new application of terbinafine combined with PD1 monoclonal antibody in the preparation of a drug for enhancing the efficacy of treating viral liver cancer. The present invention proves that terbinafine combined with PD1 monoclonal antibody can significantly inhibit the increase in the volume of viral liver cancer tumors, reduce the degree of invasion and involvement of tumor cells in the liver, and prolong the survival time of tumor mice. Terbinafine can effectively activate the immune function of CD8 T cells to kill tumor cells. When used in combination with immune checkpoint PD1 drugs, it can significantly improve the response rate of PD1 monoclonal antibody drugs to viral liver cancer treatment, providing a new treatment strategy for viral liver cancer target immune treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 This is a flow cytometric analysis of the differences in CD8 T cell proliferation in the terbinafine treatment group labeled with the fluorescent dye CFSE.
[0024] Figure 2 This is a graph showing the expression level of Ki67, a proliferation marker of CD8 T cells, in the terbinafine-treated group as detected by flow cytometry.
[0025] Figure 3 This is a graph showing the level of CD69, a T cell immune activation marker, detected by flow cytometry in the terbinafine-treated group.
[0026] Figure 4 This is a graph showing the level of immune activation cytokine IFNγ secreted by CD8 T cells in the supernatant of the terbinafine-treated group detected by ELISA.
[0027] Figure 5 This is a flow cytometry analysis of the level of PD1, a T cell immune checkpoint molecule, in the terbinafine-treated group.
[0028] Figure 6 This is a record of tumor size growth in each group of the viral liver cancer model (subcutaneous tumor-bearing Hepa1-6 mice).
[0029] Figure 7 Figure 2 shows the tumor weight of each group in the viral liver cancer model (subcutaneous tumor-bearing Hepa1-6 mice).
[0030] Figure 8 This is a record of the survival period of each group of mice with spontaneous viral liver cancer tumors.
[0031] Fig. 9 These are representative images of H&E staining in each group of mice with spontaneous viral liver cancer and statistical results of the proportion of liver area invaded by tumors. DETAILED DESCRIPTION
[0032] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0033] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0034] Example 1 Cell experiment
[0035] 1. Experimental methods
[0036] Cell lines: Human hepatocellular carcinoma cell lines SNU449 and Huh7 were purchased from ATCC cell bank.
[0037] Human hepatocellular carcinoma cell lines SNU449 and Huh7 were cultured in DMEM medium with 10% fetal bovine serum. The above cells were seeded in 96-well plates at 3,000 cells / well and cultured in a 37°C incubator containing 5% carbon dioxide. After the cells grew to 70%-80%, 20 μM terbinafine was added to the culture medium. After 2 days of drug incubation, CD8 T cells isolated from human peripheral blood were added, and CD3 and CD28 antibodies were stimulated for co-culture. Flow cytometry was performed 3 days later.
[0038] 2. Experimental results:
[0039] The results of flow cytometry detection of CD8 T cell proliferation differences in the terbinafine treatment group labeled with fluorescent dye CFSE are as follows Figure 1 As shown. Figure 1 It can be seen that in both SNU449 and Huh7 cell lines, terbinafine can significantly enhance the proliferation ability of CD8 T cells.
[0040] The results of flow cytometry detection of the expression level of CD8 T cell proliferation marker Ki67 in the terbinafine treatment group are as follows Figure 2 As shown. Figure 2 It can be seen that in the SNU449 cell line, the expression level of CD8 T cell proliferation marker Ki67 in the terbinafine-treated group was significantly ( ** In Huh7 cell line, the expression level of CD8 T cell proliferation marker Ki67 in the terbinafine-treated group was significantly higher (P<0.01). * P<0.05) was higher than that in the control group.
[0041] The results of flow cytometry detection of CD69 level, a T cell immune activation marker, in the terbinafine treatment group were as follows Figure 3 As shown. Figure 3 It can be seen that in both SNU449 and Huh7 cell lines, terbinafine can significantly ( ***P<0.001) increased the expression level of the functional activation marker CD69.
[0042] The results of ELISA detection of the level of immune activation cytokine IFNγ secreted by CD8 T cells in the supernatant of the terbinafine treatment group are as follows Figure 4 As shown. Figure 4 It can be seen that in SNU449 and Huh7 cell lines, the level of anti-tumor inflammatory factor IFNγ secreted by the terbinafine-treated group was significantly increased.
[0043] The results of flow cytometry detection of the level of PD1, a T cell immune checkpoint molecule, in the terbinafine-treated group were as follows Figure 5 As shown. Figure 5 It can be seen that in SNU449 and Huh7 cell lines, the expression of CD8 T cell immune checkpoint molecule PD1 in the terbinafine treatment group was increased ( * P<0.05).
[0044] 3. Conclusion:
[0045] In vitro cell experiments have shown that terbinafine has a significant effect on enhancing the activation of CD8 T cells and promoting their immune function, especially by upregulating the expression level of the immune checkpoint molecule PD1.
[0046] Example 2 In vivo treatment model of viral hepatocellular carcinoma subcutaneous tumor in animals
[0047] 1. Experimental methods
[0048] (1) Experimental Materials
[0049] Cell line: Mouse hepatocellular carcinoma cell line Hepa1-6 was purchased from ATCC cell bank.
[0050] Experimental animals: 8-week-old male C57BL / 6 mice were purchased from Guangdong Yaokang.
[0051] Experimental drug: Terbinafine, Shanghai BiDe Pharmaceutical Technology Co., Ltd., DLY120.
[0052] PD1 monoclonal antibody drug, BioXcell, RMP1-14.
[0053] (2) Cultivation of mouse hepatocellular carcinoma cell line Hepa1-6 and establishment of viral liver cancer model (mouse subcutaneous implantation model):
[0054] Mouse hepatocellular carcinoma cell line Hepa1-6 was cultured in DMEM medium with 10% FBS, and then placed in an incubator at 37°C and 5% CO2 for passage and growth. Cells in the logarithmic growth phase were taken, washed with PBS and digested with 0.25% trypsin, and cells were collected with PBS to make a cell suspension. The cell survival rate was greater than 92% as determined by trypan blue staining test. After adjusting the cell concentration to 10,000 cells / μl, the cells were implanted into the subcutaneous tissue of the mouse armpit within 30 minutes. The following is a brief description of the cell implantation process: 8-week-old male C57BL / 6 mice were selected, the hair was shaved from the right axilla of the mouse, and after disinfection with alcohol cotton balls, the central skin was lifted with sharp tweezers in the left hand, and 100 μL of mouse hepatocellular carcinoma Hepa1-6 cell suspension was slowly injected under the lifted skin with a 1ml medical needle syringe in the right hand. When a subcutaneous balloon-like bulge was seen, the sharp tweezers were relaxed and the needle was slowly withdrawn to prevent leakage of tumor cell suspension at the injection site during model establishment. 5-7 days after implantation, subcutaneous raised tumor boundaries were visible, proving that the mouse viral liver cancer model was successfully established.
[0055] (3) Animal grouping and drug treatment regimen:
[0056] The experimental design included four groups of mice:
[0057] Experimental group 1: untreated group (control group); Experimental group 2: terbinafine treatment group; Experimental group 3: PD1 treatment group; Experimental group 4: terbinafine combined with PD1 group,
[0058] Each group consisted of 8 mice that were successfully implanted with the Hepa1-6 viral liver cancer tumor model and received drug treatment starting on the 7th day after tumor cell inoculation.
[0059] The preparation method of terbinafine is to first dissolve it with DMSO (10%), then add PEG300 (40%) and Tween80 (5%), and finally add sterile water for injection (45%) to prepare a 100 mg / kg drug solution and gavage it to mice once a day for continuous treatment for 14 days.
[0060] The PD1 preparation method is to dilute the PD1 monoclonal antibody stock solution to 100ug / mouse with normal saline, and inject 100ul into the mouse intraperitoneally once every three days.
[0061] The mice in the control group only received normal saline gavage and intraperitoneal injection, and the gavage dose and time were the same as those in the treatment groups.
[0062] (4) Observation of therapeutic efficacy in animal experiments:
[0063] After the treatment of viral liver cancer model mice began, the tumor volume was measured every day until the 21st day. The method was to use a vernier caliper to measure the minimum diameter (a) and maximum diameter (b) of the tumor. The formula for calculating the tumor volume was: V肿瘤体积 =a 2 ×b, and record the tumor weight at the end of the experiment. To meet ethical requirements, the tumor volume of mice should be maintained below 2000mm during treatment. 3 .
[0064] 2. Experimental results:
[0065] Hepa1-6 mouse hepatocellular carcinoma cells were implanted subcutaneously in the right forelimb of C57BL / J mice, and visible tumor nodules were formed after 5-7 days. Drug treatment began on the 7th day after Hepa1-6 cell implantation, and the control group was only given solvent treatment. The long and short diameters of the implanted tumors were measured from the 6th day and continued until the 15th day. The experimental effects of single drug and combined treatment were compared by calculating tumor volume and statistical tumor weight.
[0066] The tumor size and growth of each group of subcutaneous Hepa1-6 tumor-bearing mice were recorded as follows: Figure 6 As shown. Figure 6 It can be seen that the tumor volume showed differences soon after medication, and the trend from small to large was: terbinafine combined with PD1 group (experimental group four), PD1 treatment group (experimental group three), terbinafine treatment group (experimental group two), and untreated group (experimental group one). This shows that the use of terbinafine combined with PD1 can significantly inhibit the increase of tumor volume, and the inhibitory effect is better than the use of terbinafine and PD1 monoclonal antibodies alone.
[0067] The tumor weights of each group of subcutaneous Hepa1-6 tumor-bearing mice are shown in Figure 7 As shown. Figure 7 It can be seen that compared with the untreated group, terbinafine alone can significantly reduce tumor weight; compared with the PD1 treatment group, terbinafine combined with PD1 can more significantly reduce tumor weight.
[0068] 3. Conclusion
[0069] In the viral liver cancer animal model with subcutaneous hepatocellular carcinoma cells implanted in mice, terbinafine and PD1 were administered monotherapy or combined drug treatment by oral gavage and intraperitoneal injection, respectively. The results showed that terbinafine combined with PD1 monotherapy could more significantly reduce tumor volume and tumor.
[0070] Example 3 In vivo treatment model of spontaneous viral hepatocellular carcinoma in animals
[0071] 1. Experimental methods
[0072] 8-week-old male C57BL / 6 mice (same as in Example 1) were introduced into the mice through tail vein hypertension for 2-3s. The mice were kindly donated by Chen Minshan from the Cancer Hospital of Sun Yat-sen University and the sequences were verified by sequencing by Guangzhou Ruibo Company (1. c-MYC; 2. sgTP53; 3. transposon enzyme-Luc). The mice showed mental depression in a short period of time and then returned to normal. It was expected that the fluorescence signal could be detected by the in vivo imaging instrument in 2 weeks. The drug administration scheme was the same as in Example 2, and the tumor fluorescence signal and the survival time of the mice were recorded by the in vivo imaging instrument every week. After about 6 weeks, the mice were killed when the experimental endpoint was reached, and the liver weight and the invasion of the liver by tumor cells were recorded. The liver tumor tissue was collected for paraffin embedding and sectioning, and the area ratio of the liver area occupied by the tumor was marked by H&E staining.
[0073] 2. Experimental results
[0074] The survival time of each group of mice with spontaneous viral hepatocellular carcinoma was recorded as follows: Figure 8 As shown. Figure 8 It can be seen that mice in the control group and the single drug group began to die on the 15th to 23rd day, and the mortality rate reached 100% on the 32nd day; while the terbinafine combined with PD1 group did not die until the 21st day, and the mortality rate was only about 25% on the 40th day. The survival curve drawn by the Kaplan-Meier method was found after the Log-Rank test that the combined treatment group significantly prolonged the survival time of mice compared with the single drug group and the control group.
[0075] Representative images of H&E staining in each group of mice with spontaneous viral hepatocellular carcinoma and statistical results of the proportion of liver area invaded by tumors are shown in the figure. Fig. 9 As shown. Based on the H&E staining, the percentage of liver area occupied by tumor was counted and it was found that the percentage of liver area occupied by tumor in the terbinafine combined with PD1 group was significantly reduced to about 60% compared with the untreated group (P<0.0001). This indicates that the use of terbinafine combined with PD1 can significantly reduce the degree of tumor cell invasion and involvement of the liver.
[0076] 3. Conclusion
[0077] In the viral liver cancer model in which spontaneous hepatocellular carcinoma was induced by high-pressure tail vein injection of tumorigenic plasmids in mice, terbinafine and PD1 were administered monotherapy or combined with other drugs by oral gavage and intraperitoneal injection, respectively. The results showed that terbinafine and PD1 monotherapy had limited control over disease progression, but their combined use could significantly prolong the survival of mice, significantly reduce the tumor invasion area, and effectively enhance the anti-tumor immune function of CD8 T cells infiltrating the tumor. This demonstrates that the combination of terbinafine and PD1 has a significant therapeutic effect on the viral liver cancer model that is unresponsive to PD1 treatment.
[0078] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. The application of terbinafine in the preparation of a synergist of immunotherapy drugs for viral liver cancer.
2. The use of terbinafine in the preparation of drugs for treating viral liver cancer.
3. Application of terbinafine combined with immunotherapy drugs in the preparation of drugs for enhancing the efficacy of viral liver cancer.
4. Application of terbinafine combined with immunotherapy drugs in the preparation of drugs for the treatment of viral liver cancer.
5. The use according to any one of claims 1, 3 and 4, characterized in that: The immunotherapy drug is PD1 monoclonal antibody.
6. The use according to any one of claims 1 to 4, characterized in that: The drug refers to a drug that can inhibit the increase in the volume of viral liver cancer tumors.
7. The use according to any one of claims 1 to 4, characterized in that: The drug is a drug that can prolong the survival time of patients with viral liver cancer.
8. The use according to any one of claims 1 to 4, characterized in that: The drug refers to a drug that can reduce the degree of invasion of the liver by tumor cells of patients with viral liver cancer.
9. A drug for treating viral liver cancer, characterized in that: The medicine comprises terbinafine and an immunotherapy drug, and a pharmaceutically acceptable carrier.
10. The drug according to claim 9, characterized in that The immunotherapy drug is PD1 monoclonal antibody.
